UnitedHealth raises profit target again and significantly exceeds analyst expectations

In the second quarter, the group earned adjusted earnings per share of $6.38, while market consensus had only expected an average of around $4.90. The quarterly profit even exceeded the most optimistic estimate. However, net income rose by more than 60 percent to almost $5.5 billion. Group revenue increased only slightly year-over-year to around $112 billion (roughly €98 billion) and was thus above the analyst expectation of around $111 billion.

Medical treatment costs developed significantly better in the second quarter than analysts had expected. The loss ratio fell to 86.7 percent, after 89.4 percent in the prior-year quarter – significantly better than the roughly 88.5 percent that analysts had expected. These would have proven to be consistent in the following months.

Treatment costs develop more favorably

CFO Wayne DeVeydt attributes this, according to Reuters, to changed tariff design and more targeted pricing, but at the same time warns against seeing this as a sustainable trend reversal: costs remained structurally elevated, the company was only pushing them back in a targeted way. „Wir haben im ersten Quartal erste Anzeichen einer Erholung gesehen, die für uns sehr ermutigend waren,“ said DeVeydt further.

The Optum segment contributed operating earnings of $4.0 billion, an increase of 29 percent compared with the prior-year quarter, after the business had recorded a decline in the first quarter. The UnitedHealthcare insurance business improved its operating margin to 4.6 percent from 2.4 percent in the prior-year quarter, while membership declined slightly due to the withdrawal from parts of the Obamacare market and declining Medicare Advantage numbers.

AI investments and the Optum segment

Until then, it remains unclear how strongly the planned decline in Obamacare membership will affect the revenue side. The company is now selling business units, is supposed to serve fewer customers and earn less, but generate more profit. UnitedHealth announced investments of $1.5 billion in artificial intelligence. According to DeVeydt, these tools are already reducing administrative burdens and giving physicians more time for patient care.

The markets welcomed the news: on the NYSE, the stock rose temporarily by 6.86 percent to $447.22. In the past three months alone, the stock had gained substantially, rising 32.28 percent. Analysts also reacted cautiously optimistic – Goldman Sachs had already rated UnitedHealth „buy“ on 17/07/18, RBC Capital Markets upgraded the stock to „Outperform“ on 14/10/20, and Credit Suisse Group followed on 15/10/20 also with „Outperform“.

Background: 2025 crisis and return of Hemsley

The background to this turnaround is the group's crisis in 2025. The long-standing group CEO had taken over the leadership of UnitedHealth again during its 2025 crisis and prescribed the company a course of contraction. Hemsley returned to the top of the group after missed profit targets and a consequential cyberattack, replaced roughly half of the executive team before the former chief Hemsley switched back to the top. Management cut its annual targets and later scrapped them entirely due to high medical treatment costs. In 2025, UnitedHealth repeatedly came under the scrutiny of government investigations. In April, Hemsley had already raised the bar for adjusted earnings per share this year to more than $18.25.

The next quarterly figures are usually expected in October. It will then become apparent whether the restructuring announced in spring actually leads to a sustainable trend reversal or whether the structurally elevated costs continue to burden the group. The report was authored by Martina Köhler, editorial team at finanzen.net.